Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of August 11th - 17th, 2023.



He begins by highlighting the FDA approval of niraparib and abiraterone acetate with prednisone for treating of BRCA mutated castration-resistant prostate cancer.



Dr Morgan also covers results from the TITAN trial which used apalutamide versus placebo for patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy.

In addition, he comments on the PERNETTA trial, which involved the use of pertuzumab and trastuzumab followed by emtansine for ERBB2-positive metastatic breast cancer.

Follow Dr Morgan on twitter: @OncoAlert

Follow ecancer on twitter: @ecancer